Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Neoplasms 6Multiple Myeloma 4Kidney Neoplasms 3Colonic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Waldenstrom Macroglobulinemia 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Recurrence 1Lymphoma 1Liver Neoplasms 1Leukemia 1Gastrointestinal Stromal Tumors 1Colorectal Neoplasms 1Chondrosarcoma 1Carcinoma, Renal Cell 1Breast Neoplasms 1

Interventions

Rituximab 63Cyclophosphamide 37Brentuximab Vedotin 22Bendamustine Hydrochloride 22pembrolizumab 20fludarabine 20Gemcitabine 20Doxorubicin 20Prednisone 19ibrutinib 17Vincristine 16obinutuzumab 14Lenalidomide 13Nivolumab 10Rifampin 8parsaclisib 7duvelisib 7atezolizumab 7Vorinostat 7Dexamethasone 7Azacitidine 7spartalizumab 6loncastuximab tesirine 6MLN 8237 6venetoclax 5ixazomib 5glofitamab 5fludarabine phosphate 5durvalumab 5acalabrutinib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Lymphoma × perifosine × Clear all
NCT00389077 2018-03-07

Trial of Two Schedules of Perifosine for Patients With Solid Tumors or Lymphomas

AEterna Zentaris

Phase 2 Completed
558 enrolled
Lymphoid

Lymphoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡